CRISPR Startups Fight Back Against CRISPR Off-Target Report

Antonio Regalado, 9 June 2017, MIT Technology Review,

In response to the Nature Methods Letter outlining potential off-target effects introduced by CRISPR/Cas9 genome editing, Intellia Therapeutics and Editas medicine have penned separate letters to the journal outlining their concerns with the report.  Nessan Bermingham, CEO of Intellia, went so far as to call on Nature Methods to retract the Letter, “given the issues around the design and interpretation.”  Nature Methods has stated that they are considering the concerns and discussing them with the authors.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply